Sciatica is not a diagnosis — it is a symptom of a compressed or irritated nerve root in the lumbar spine. The hallmark is pain that travels from the lower back through the buttock and down the leg, following the path of the sciatic nerve — the longest and widest nerve in the human body, formed by nerve roots from L4 through S3. An estimated 10–40% of the population will experience at least one episode of sciatica in their lifetime, and a substantial proportion go on to develop chronic, disabling radicular pain that resists conventional treatment.[1]

The most common cause is a herniated lumbar disc. When the soft nucleus pulposus breaches the fibrous annulus at L4–L5 or L5–S1, it can compress the adjacent nerve root — not just mechanically, but chemically. The extruded disc material triggers a potent inflammatory response, with elevated levels of TNF-α, IL-1β, IL-6, and prostaglandin E2 at the nerve root interface. This neuroinflammation — not mechanical compression alone — is what drives the characteristic burning, tingling, numbness, and weakness that define sciatica.

Conventional treatments bypass the biology. NSAIDs temporarily reduce prostaglandin synthesis but do not resolve the underlying cytokine cascade. Epidural steroid injections suppress inflammation locally but carry diminishing returns with repeated use and do not address disc integrity. For the roughly 10–20% of patients whose symptoms persist beyond 6–12 weeks, the pathway narrows to microdiscectomy — effective at removing the mechanical compression, but leaving the inflammatory milieu and disc degeneration unaddressed.

MSC therapy targets the nerve root environment directly. Mesenchymal stem cells do not simply mask pain — they engage the inflamed tissue and release a coordinated cocktail of anti-inflammatory mediators and neurotrophic factors. When delivered to the epidural space at the level of nerve root compression, MSCs can reduce local cytokine levels, support neural tissue integrity, and shift the local immune environment from degeneration toward regeneration.[2]

What Is Actually Happening at the Compressed Nerve Root

To understand why sciatica is so persistent, it helps to look at what happens at the nerve root interface. The dorsal root ganglion (DRG) — a cluster of sensory neuron cell bodies located just outside the spinal cord — is exquisitely sensitive to mechanical and chemical insult. When a herniated disc contacts the DRG or the nerve root, the extruded nucleus pulposus releases pro-inflammatory cytokines that sensitize nociceptors, lower the firing threshold of sensory neurons, and trigger ectopic discharges — signals sent to the brain even in the absence of a normal stimulus.[3]

This process has three overlapping components:

This is why painkillers alone rarely provide lasting relief for chronic sciatica — they address only the descending pain signalling without touching the neuroinflammatory process that sustains it.

Cross-section of herniated intervertebral disc compressing nerve root with inflammatory cytokine activity at compression site
Chemical radiculitis — not just mechanical compression — sustains the neuroinflammatory cycle that MSC therapy targets at the nerve root interface.

How MSC Therapy Works for Sciatica

When clinical-grade MSCs are delivered to the epidural space near the compressed nerve root — typically via transforaminal epidural injection under fluoroscopic guidance — they engage the inflammatory environment through several coordinated mechanisms:[4]

1. They neutralize the cytokine storm at the nerve root

MSCs sense the high concentrations of TNF-α and IL-1β and respond by releasing powerful anti-inflammatory mediators — TSG-6, PGE2, IL-10, and IDO. TSG-6 in particular directly inhibits neutrophil migration, reduces macrophage activation, and dampens the cytokine cascade at its source. Within the epidural space, this can begin reducing radicular pain and sensory disturbances within the first few weeks after treatment.

2. They release neurotrophic and neuroprotective factors

MSCs secrete brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF), and insulin-like growth factor-1 (IGF-1) — signalling molecules that support axonal integrity, promote Schwann cell activity, and protect neurons from apoptosis. At the compressed nerve root, this creates a biochemical environment that favours neural repair over ongoing degeneration.[5]

3. They modulate the local immune response

MSCs reprogram macrophages from a pro-inflammatory M1 phenotype to a regenerative M2 phenotype. In the context of disc herniation, this shift reduces the autoimmune-like response to exposed nucleus pulposus material, dampening the chronic inflammation that sustains radiculopathy long after the initial mechanical insult has resolved.[6]

4. They support disc matrix preservation

While the primary target in sciatica is the nerve root, MSCs also benefit the degenerating disc itself. Paracrine factors including TGF-β and BMP-7 signal resident disc cells to maintain proteoglycan and collagen synthesis, potentially slowing the progression of the disc degeneration that underlies recurrent herniation.[7]

What MSC Therapy Does NOT Do for Sciatica

Honest expectations matter. MSC therapy does not physically remove a herniated disc fragment. It does not reverse severe cauda equina syndrome, restore complete motor function in a long-standing foot drop, or correct advanced spinal stenosis. What it can do is reduce the neuroinflammation driving radicular pain, support nerve root healing, and potentially avoid or delay the need for surgical decompression in carefully selected patients with moderate herniation and persistent symptoms who have not progressed to severe neurological deficit.[8]

Who Is a Good Candidate for MSC Therapy in Sciatica?

The best outcomes are seen in patients whose sciatica is driven by neuroinflammation rather than purely mechanical compression. These are typically individuals who:[9]

The role of the consultation — including a thorough MRI review, neurological examination, and functional assessment — is to distinguish inflammatory radiculopathy from surgical disc disease and determine whether regenerative therapy is appropriate for the individual patient.

What the Treatment Process Looks Like

At a clinical-grade centre, a typical sciatica-focused MSC protocol follows a structured pathway:

Step 1: Comprehensive Assessment

Lumbar MRI, neurological examination (sensory, motor, reflexes), pain mapping, and inflammatory biomarker evaluation. The goal is to identify the precise level of nerve root involvement — most commonly L4–L5 or L5–S1 — and confirm that neuroinflammation, not severe mechanical compression or instability, is the primary driver of symptoms.

Step 2: Protocol Design

The clinical team tailors the approach: transforaminal epidural injection under fluoroscopic guidance (the preferred route for sciatica, as it delivers MSCs directly to the affected nerve root), with or without supplementary IV infusion for systemic anti-inflammatory support. Dose, timing, and adjunctive physiotherapy are determined individually.

Step 3: Treatment Delivery

The transforaminal epidural injection is performed under real-time fluoroscopy or CT guidance, ensuring precise MSC placement at the nerve root–disc interface. The procedure is outpatient, takes 60–90 minutes including preparation, and patients walk out the same day with light activity restrictions.

Step 4: Recovery and Rehabilitation

A structured rehabilitation programme — including nerve gliding exercises, core stabilisation, postural retraining, and gradual return to activity — complements the cellular therapy. Most protocols recommend 48–72 hours of light activity followed by a graduated return to normal mobility over 2–4 weeks.

Step 5: Outcome Monitoring

Follow-up at 4, 12, and 24 weeks tracks pain using validated scales (Visual Analog Scale and Oswestry Disability Index), sensory and motor function, quality of life, and where clinically indicated, repeat MRI to assess disc and nerve root status.

Fluoroscopy-guided transforaminal epidural injection delivering MSC therapy to nerve root with glowing cellular particles
Transforaminal epidural delivery under fluoroscopy places MSCs at the precise nerve root interface — the site of neuroinflammation in sciatica.

Realistic Timelines: What to Expect and When

Cellular therapy follows a biological timeline, not a pharmacological one. Most patients experience response in three overlapping phases:[10]

2–4 weeks Initial reduction in neuroinflammatory pain, burning, and tingling
8–12 weeks Functional improvement: reduced leg pain, improved walking tolerance, better sleep
6–12 months Sustained benefit window; some patients return for maintenance

Outcomes depend on disc herniation severity, duration of symptoms, nerve root involvement, MSC quality, dosing protocol, and the quality of the surrounding rehabilitation programme. A reputable clinic will be transparent about the proportion of patients experiencing strong, moderate, and limited benefit.

Safety and What Every Patient Should Know

When delivered with clinical-grade cells, image-guided technique, and appropriate clinical oversight, MSC therapy for sciatica has an excellent safety profile. The most common side effects are local: temporary post-injection soreness, mild stiffness, or a brief increase in radicular discomfort for 24–72 hours — likely reflecting the initial inflammatory response to the injection itself. Serious adverse events are rare in the published literature when GMP-grade cells and fluoroscopic guidance are used.[11]

The most significant preventable risk in this field is not the therapy itself — it is unregulated providers using non-clinical-grade cells with unverified sterility, identity, and potency. Patients should always confirm: MSC source and characterization (≥95% CD73/CD90/CD105 positive, ≤2% CD45/CD34/CD14 positive), laboratory certifications (ISO, GMP), and access to a Certificate of Analysis for the specific dose being administered.[12]

For the right patient — a contained disc herniation causing persistent radiculopathy with an inflammatory component — MSC therapy can offer meaningful relief without the recovery burden of surgery. The key is honest candidacy assessment before treatment begins.

— VELAR Clinical Team

The VELAR Approach to Sciatica

Sciatica protocols at VELAR Center begin with comprehensive MRI review, neurological examination, and biomarker assessment to map the precise nerve root involvement and confirm candidacy. Each protocol uses clinical-grade Wharton's jelly–derived MSCs (≥95% MSC marker expression, >90% post-thaw viability), delivered via transforaminal epidural injection under fluoroscopic guidance — with or without IV infusion depending on symptom severity and distribution. Every session is led by an experienced clinician, paired with structured neurorehabilitation, and monitored across the 1-, 3-, and 6-month milestones.[8]

If you are considering regenerative therapy for sciatica, the most important first step is an honest assessment of whether your specific disc pathology and symptom pattern are likely to respond — and a clear understanding of realistic outcomes for your stage of nerve root involvement.

Frequently Asked Questions

How much does stem cell therapy for sciatica cost in Thailand?

MSC therapy for sciatica in Thailand typically ranges from USD 6,000 to 12,000 depending on protocol complexity (single vs. combined delivery routes), cell dose, and whether adjunctive IV infusion is included. This is significantly lower than in the US or Europe, where comparable protocols often exceed USD 20,000.

Can MSC therapy replace surgery for a herniated disc?

MSC therapy may reduce or eliminate the need for microdiscectomy in carefully selected patients — those with contained disc herniations, inflammatory radiculopathy, and no progressive neurological deficits. It does not replace surgery for patients with large free fragments, cauda equina syndrome, or rapidly progressive motor weakness. An honest MRI-based assessment determines which path is appropriate.

How many MSC injections are needed for sciatica?

Most protocols involve a single transforaminal epidural injection session, sometimes combined with an IV infusion. Some patients with bilateral or multi-level involvement may benefit from a series of 2–3 sessions spaced 4–8 weeks apart. The exact protocol is determined after MRI review and neurological examination.

What is the success rate of stem cell therapy for sciatica?

Published studies on epidural MSC delivery for discogenic radiculopathy report that 60–75% of carefully selected patients experience clinically meaningful pain reduction (≥50% improvement on VAS) and functional gains at 6–12 months. Outcomes are strongest in patients with contained herniations, inflammatory-predominant symptoms, and symptoms present for less than 2 years.

Is MSC therapy for sciatica painful?

The transforaminal epidural injection itself involves brief local anaesthetic administration followed by the MSC injection under fluoroscopy — most patients describe it as pressure rather than pain. Post-procedure soreness at the injection site and a temporary increase in radicular discomfort lasting 24–72 hours is common and typically resolves with rest and ice.

How soon can I return to work after MSC therapy for sciatica?

Desk-based work can typically resume within 2–3 days. Physically demanding occupations may require 2–4 weeks of modified duties. The full biological response to MSC therapy develops over 2–3 months, so a gradual return to high-impact activities is recommended even if pain improves earlier.

References

  1. Stafford MA, Peng P, Hill DA. Sciatica: a review of history, epidemiology, pathogenesis, and the role of epidural steroid injection in management. British Journal of Anaesthesia. 2007;99(4):461-473. doi:10.1093/bja/aem238 ↩
  2. Urits I, Capuco A, Sharma M, et al. Stem cell therapies for treatment of discogenic low back pain: a comprehensive review. Current Pain and Headache Reports. 2019;23(9):65. doi:10.1007/s11916-019-0804-y ↩
  3. Valat JP, Genevay S, Marty M, Rozenberg S, Koes B. Sciatica. Best Practice & Research Clinical Rheumatology. 2010;24(2):241-252. doi:10.1016/j.berh.2009.11.005 ↩
  4. Centeno C, Markle J, Dodson E, et al. Treatment of lumbar degenerative disc disease-associated radicular pain with culture-expanded autologous mesenchymal stem cells: a pilot study on safety and efficacy. Journal of Translational Medicine. 2017;15(1):197. doi:10.1186/s12967-017-1300-y ↩
  5. Wilkins A, Kemp K, Ginty M, Hares K, Mallam E, Scolding N. Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Research. 2009;3(1):63-70. doi:10.1016/j.scr.2009.02.006 ↩
  6. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11-15. doi:10.1016/j.stem.2011.06.008 ↩
  7. Sakai D, Schol J. Cell therapy for intervertebral disc repair: clinical perspective. Journal of Orthopaedic Translation. 2017;9:8-18. doi:10.1016/j.jot.2017.02.002 ↩
  8. Meisel HJ, Agarwal N, Hsieh PC, et al. Cell therapy for treatment of intervertebral disc degeneration: a systematic review. Global Spine Journal. 2019;9(1 Suppl):39S-52S. doi:10.1177/2192568219829024 ↩
  9. Pettine KA, Murphy MB, Suzuki RK, Sand TT. Percutaneous injection of autologous bone marrow concentrate cells significantly reduces lumbar discogenic pain through 12 months. Stem Cells. 2015;33(1):146-156. doi:10.1002/stem.1845 ↩
  10. Noriega DC, Ardura F, Hernández-Ramajo R, et al. Intervertebral disc repair by allogeneic mesenchymal bone marrow cells: a randomized controlled trial. Transplantation. 2017;101(8):1945-1951. doi:10.1097/TP.0000000000001484 ↩
  11. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905 ↩
  12. Orozco L, Soler R, Morera C, Alberca M, Sánchez A, García-Sancho J. Intervertebral disc repair by autologous mesenchymal bone marrow cells: a pilot study. Transplantation. 2011;92(7):822-828. doi:10.1097/TP.0b013e3182298a15 ↩